Frontlight ResearchEarly access
Taking people in DenmarkPhase 1
Nivolumab and ipilimumab before surgery for high-risk uveal melanoma
Tests nivolumab and ipilimumab given beforehand in adults with high-risk uveal melanoma.
Key facts
- Who runs it
- Region Hovedstaden
- Where
- Herlev, DenmarkSee the site
- Trial code
- Registry title
- Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Started
- 29 Jun 2026
- Expected to end
- 1 Apr 2029
- Type of study
- Interventional
- Record updated
- 4 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high-risk uveal melanoma who would receive nivolumab and ipilimumab before surgery.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- High-risk uveal melanoma
Where in Denmark
- Herlev HospitalHerlev, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Nivolumab and ipilimumab before surgery for high-risk uveal melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 4 February 2026